title: Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.
abstract: Although glycemic control is an important and effective way to prevent and minimize the worsening of diabetes-related complications, type 2 diabetes is a progressive disease which often proves difficult to manage. Most affected patients will eventually require therapy with multiple medications in order to reach appropriate glycemic targets. The dipeptidyl peptidase-4 (DPP-4) inhibitors constitute a relatively new class of oral medications for the treatment of type 2 diabetes, which has become widely incorporated into clinical practice. This review summarizes the available data on the efficacy, safety, and tolerability of these medications.
authors.affiliation: Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition. Duke University Medical Center, Durham, NC, USA;
authors.forename: Mary Elizabeth
authors.initials: ME
authors.lastname: Cox
authors.forename: Jennifer
authors.initials: J
authors.lastname: Rowell
authors.forename: Leonor
authors.initials: L
authors.lastname: Corsino
authors.forename: Jennifer B
authors.initials: JB
authors.lastname: Green